PRA Health Sciences Inc

PRA Health Sciences — Merger or Acquisition (February 2021)

36 slides from PRA Health Sciences's merger presentation, Feb 24, 2021

  1. Slide 1: Creating A World Leading Healthcare Intelligence and Clinical CRO

    Slide 1: Creating A World Leading Healthcare Intelligence and Clinical CRO

    Creating A World Leading Healthcare Intelligence and Clinical CRO Transaction Announcement February 24", 2021

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forwar oking Stateme:

  3. Slide 3: Today's presenters

    Slide 3: Today's presenters

    Today’s presenters Dr. Steve Cutler CEO Brendan Brennan CFO Colin Shannon President, CEO

  4. Slide 4: ICON & PRA Health Sciences

    Slide 4: ICON & PRA Health Sciences

    ICON & PRA Health Sciences Creating a leading healthcare intelligence and clinical CRO 0600 #6 Clinical CRO' Headquarters in Dublin, Ireland Headquarters in ~16k Headcount / Offices in 41 countries Headcount / Offices in ~$2.8bn revenues? revenues? A Global CRO Leader ~35k Combined Headcount ~$6.0bn

  5. Slide 5: Together, we are stronger

    Slide 5: Together, we are stronger

    Together, we are stronger Combination creates a world leading healthcare intelligence and clinical CRO service & geographic offerings, deeper therapeutic & nctional capabilities, tive DNA with best-in-class clinical trial technology 8 centralized and hybrid trial solutions. ps with majority of world

  6. Slide 6: Significant growth and shareholder value creation expected

    Slide 6: Significant growth and shareholder value creation expected

    Significant growth and shareholder value creation expected Long-Term Growth Outlook Cost and Revenue Synergies Shareholder Value Revenue CAGR: high single digits ‘Adj. EBITDA CAGR: low-teens ‘Adj EPS CAGR: mid-teens + $150mm run-rate cost synergies fully realized in ~4 years Significant potential fo

  7. Slide 7: Transaction summary

    Slide 7: Transaction summary

    Transaction summary Leadership / Governance $12bn cash and stock transaction ‘$80 per share in cash and 0.4125 shares of ICON stock based on a fixed exchange ratio PRA shareholders will own ~34% of the combined company Premium of ~30% to PRA’s closing price as of February 23°, 2021 Pro forma net deb

  8. Slide 8: Investment highlights

    Slide 8: Investment highlights

    Investment highlights

  9. Slide 9: As healthcare markets change, customer needs are evolving

    Slide 9: As healthcare markets change, customer needs are evolving

    As healthcare markets change, customer needs are evolving RO market is cl Shift to emerging therapies e.g. Cell & Gene, requires deeper expertise at CROs Speed to market during Covid re-setting development timeline expectations ‘Accelerated adoption of telemedicine & digitization - ‘growing use of d

  10. Slide 10: Together, we will create a leading clinical CRO

    Slide 10: Together, we will create a leading clinical CRO

    Together, we will create a leading clinical CRO... $Bn Estimated 2020 CRO Revenue’ $5.8 $5.7 $4.90 $4.7 $3.3 $2.9 $2.8 $2.8 $0.9 OAL | CO.N] PPD CLC ON) PAREXEL PACE

  11. Slide 11: With enhanced global footprint and leadership in key geographies

    Slide 11: With enhanced global footprint and leadership in key geographies

    With enhanced global footprint and leadership in key geographies.

  12. Slide 12: A Diversified Business

    Slide 12: A Diversified Business

    A Diversified Business... Well-Represented in All 5 Customer Segments? ee le A 7BN % 4 Cardiovascular Lage Blopharma Hepatology Bl Endocrinology I Smal, Mid & Emerging pharma MAlone:——Gastoenteoogy Largest Customer <10% of Direct peig abe Diversified Therapeutic Portfolio? Based on combined 2020 CYE

  13. Slide 13: Segment leadership

    Slide 13: Segment leadership

    12 in Segment #1.¢RO in Segment Late Phase / RWE #3 in Sogment 14 in Segment Innovative RIVE Solutions Broader Cross-seling opportunites ICON Stes ICO RWE Operas ICON Weara Language Services

  14. Slide 14: With a suite of tools to create a new paradigm for bringing clinical research to patients

    Slide 14: With a suite of tools to create a new paradigm for bringing clinical research to patients

    With a suite of tools to create a new paradigm for bringing clinical research to patients sie newen ‘OneSearch Pediatric Site Network Patient Clinical Trial Matching DeepLens = AUML EHR Trial Matching Recess to Patients le Heath Patform Real Innovations Worta ables Data IAP Cinical Outcome site Plat

  15. Slide 15: Financial highlights

    Slide 15: Financial highlights

    Financial highlights

  16. Slide 16: Strong track record of shareholder value creation

    Slide 16: Strong track record of shareholder value creation

    Strong track record of shareholder value creation since 2015! +426% +308% +186% +184% NASDAQ Peer composite?

  17. Slide 17: Position of strength — Strong Q4 2020 reported performance

    Slide 17: Position of strength — Strong Q4 2020 reported performance

    Position of strength — Strong Q4 2020 reported performance Revenue $760m YoY Growth 49.1% Margi 17.5% YoY Growth 42.7% YoY Growth +0.6%

  18. Slide 18: Strong growth expected

    Slide 18: Strong growth expected

    Strong growth expected Revenue Y High single digits = Robust standalone momentum ~ Strength across all customer sizes ~ Excludes impact of revenue synergies Adj. EBITDA v = Strong-track record of bestin-class ost management expertise = Optimizing footprint = Duplicative infrastructure Significant ta

  19. Slide 19: Significant cost and tax synergies

    Slide 19: Significant cost and tax synergies

    icant cost and tax synergies = Optimizing business processes = Leveraging global support infrastructure = Optimizing IT infrastructure ~ Reducing corporate costs ~ Facilities-related savings $150mm run-rate cost synergies fully realized in ~4 years = Targeting ~14% blended tax rate within ~4 years ~

  20. Slide 20: Free cash flow generation to drive rapid deleveraging and support growth

    Slide 20: Free cash flow generation to drive rapid deleveraging and support growth

    Free cash flow generation to drive rapid deleveraging and support growth Total Sources: $13.5 Total Uses $13.5 Rapid deleveraging driven by expected strong free cash flow generation o—_ @ Anticipated pro forma cap table New Term Loan $4.0 Other Secured Indebtedness. 2.0 Total Gross Debt $6.0 Net Deb

  21. Slide 21: Together, we are stronger

    Slide 21: Together, we are stronger

    Together, we are stronger Combination creates a world leading healthcare intelligence and clinical CRO service & geographic offerings, deeper therapeutic & nctional capabilities, tive DNA with best-in-class clinical trial technology 8 centralized and hybrid trial solutions. ps with majority of world

  22. Slide 22: Our shared mission is to innovate to save lives — together, we can go even faster

    Slide 22: Our shared mission is to innovate to save lives — together, we can go even faster

    Our shared mission is to innovate to save lives — together, we can go even faster PRA Health Sciences We help change people's OCOD Our mission is to Inpeveting ‘accelerate the to lives for the better every development of drugs save lives single day. It's who we are. and devices that save Innovating

  23. Slide 23: Appendix

    Slide 23: Appendix

    Appendix

  24. Slide 24: 2020 CYE Reconciliation of Pro Forma Financials

    Slide 24: 2020 CYE Reconciliation of Pro Forma Financials

    2020 CYE Reconciliation of Pro Forma Financials Revenue $2,797.3m $3,183.4m $5,980.7m YoY Growth (0.3%) 3.8% Net income attributable to ICON / PRA (GAAP) $3323m $197.0m $529.4m Net income attributable to noncontroliing interest $0.6m. - $0.6m Share of equity method investments 0.4m - 0.4m Depreciati

  25. Slide 25: ICON Q4 & FY 2020

    Slide 25: ICON Q4 & FY 2020

    ICON Q4 & FY 2020

  26. Slide 26: Backlog metrics

    Slide 26: Backlog metrics

    Backlog metrics ($bn) ame 87% 8.3% 78% 8.1% 7.1% Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 mm Closing Backlog Burn rate

  27. Slide 27: Revenue: quarterly & annual

    Slide 27: Revenue: quarterly & annual

    Revenue: quarterly & annual ($m) 725 15 702 760 _ 2,806 2,797 $m Q42019 Q1 2020 Q22020 Q3 2020 Q4 2020 FY 2019 FY 2020 err,

  28. Slide 28: Gross margin: quarterly and annual

    Slide 28: Gross margin: quarterly and annual

    Gross margin: quarterly and annual Percentage of Revenue 725 715 702 620 $m i J Q42019 Q12020 Q22020 Q32020 a4 2020 mm Revenue —Gross Margin % 760 2,806 2,797 FY 2019 FY 2020

  29. Slide 29: SG&A: quarterly and annual

    Slide 29: SG&A: quarterly and annual

    SG&A: quarterly and annual Percentage of Revenue 760 725 715 702 620 ee 118% 11.08% Q42019 Q12020 Q22020 Q32020 a4 2020 mmRevenue. —SG&A% 2,806 2,797 120% FY 2019 FY 2020 errr,

  30. Slide 30: Operating margin: quarterly and annual

    Slide 30: Operating margin: quarterly and annual

    Operating margin: quarterly and annual Percentage of Revenue 725 715 702 620 $m 15.9% 154% 121% 760 Q4 2019 Q1 2020 Q22020* Q3 2020 Q42020 mm Revenue Excludes impact of nonrecurring charges, 2,806 2,797 15.4% FY 2019 FY 2020*

  31. Slide 31: Earnings per Share attributable to the group: quarterly and annual

    Slide 31: Earnings per Share attributable to the group: quarterly and annual

    Earnings per Share attributable to the group: quarterly and annual 183 190 4170 172 6.88 6.53 120 Q42019 Q12020 Q22020* Q32020 a4 2020 FY 2019 FY 2020* * Excludes impact of non-recurring charges. so

  32. Slide 32: Balance sheet and cash flow

    Slide 32: Balance sheet and cash flow

    Balance sheet and cash flow FY 2020 FY 2019 31-Dec-20 31-Dec-19 Dso" re 54 Capital Expenitur $51.1m $50,6m Cash from Operating Activities $568.0m $4125m ssh Balanc $493.6m Gross Cash Balance $842.0m Gross Debt $350.0m $350.0m Calculated on a comparative non-GAAP basis. * Reflects principal value.

  33. Slide 33: Q4 year-on-year comparison summary

    Slide 33: Q4 year-on-year comparison summary

    Q4 year-on-year comparison summary Revenue* $760m $725m Gross Margin 29.6% 29.9% SG&A (percentage of revenue) 11.6% 11.9% Operating Margin 15.8% 15.9% Net Income attributable to Group (percentage of revenue) 13.3% 13.6% EPS attributable to Group 190¢ 183¢ * 4.8% reported increase. 3.3% constant curr

  34. Slide 34: FY year-on-year comparison summary

    Slide 34: FY year-on-year comparison summary

    FY year-on-year comparison summary Revenue’ $2,797m $2,806m Gross Margin 29.2% 29.6% SG8A (percentage of revenue) 12.2% 12.0% Operating Margin 14.6% 15.4% Net Income attributable to Group (percentage of revenue) 12.4% 13.3% EPS attributable to Group $6.53 $6.88 * Excludes impact of non securing char

  35. Slide 35: FY 2021 guidance — ICON Standalone

    Slide 35: FY 2021 guidance — ICON Standalone

    FY 2021 guidance — ICON Standalone P| cance | ative rears Revenue $3,200m - $3,300m 14.4% - 18.0% EPS $8.10 - $8.50 24.0% - 30.2%

  36. Slide 36: iconplc.com

    Slide 36: iconplc.com

    iconplc.com mn @re

Source: SEC EDGAR · 425 filed Feb 24, 2021

More decks from PRA Health Sciences Inc